# Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis

> **NCT02296775** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dr. Reddy's Laboratories Limited** · enrollment: 276 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** DRL_RI
- **BIOLOGICAL:** Rituxan
- **BIOLOGICAL:** MabThera

## Key facts

- **NCT ID:** NCT02296775
- **Lead sponsor:** Dr. Reddy's Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2016-11
- **Final completion:** 2017-10-05
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2020-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02296775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02296775, "Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02296775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*